China Orders All Injectables Inspected In Wake Of Three Deaths
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA ordered its local bureaus around the country to inspect all intravenous injectables by the end of the year to ensure none is contaminated. The agency took the action in the wake of at least three incidents in which people died after receiving an injection with an herb produced by Wandashan Pharmaceutical, later found to be contaminated with bacteria. SFDA bureaus were instructed to determine how an injection was produced, its ingredients, equipment used and other information through quality spot-checks and risk evaluation. (Click here for more
You may also be interested in...
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.